Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

Our list of top things to do this weekend includes theater productions, a circus, a chocolate festival and more ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ...

Synthetic biologists from Yale were able to re-write the genetic code of an organism—a novel genomically recoded organism ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

Military has finally seen the light of day. The fan-made modification, which has been in development since 2018, allows ...

Synthetic biologists from Yale were able to re-write the genetic code of an organism - a novel genomically recoded organism (GRO) with one stop codon - using a cellular platform that they developed ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

Synthetic biologists from Yale were recode the genetic code of an organism, a novel genomically recoded organism (GRO) with ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. "In ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...